Quantum BioPharma Announces Debt Settlement, Equity Grants, and Advisor Departure
Quantum BioPharma has settled outstanding debt through share issuance, granted restricted share units tied to regulatory milestones for its Lucid MS program, and terminated an advisor agreement, reflecting strategic financial and clinical development moves.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91), a biopharmaceutical company developing treatments for neurodegenerative, metabolic and alcohol misuse disorders, announced several corporate actions. On August 12, 2025, the board approved settlement of $26,812.50 in outstanding debt through the issuance of 1,102 Class B shares at a deemed price of $24.33 per share. On August 15, 2025, the board granted 800 restricted share units each to clinical advisors Peter Stys and Jack Antel under the equity incentive plan, with vesting tied to regulatory milestones for the company’s Lucid MS program.
The creditor shares and RSUs are subject to a four-month-plus-one-day statutory hold under CSE policy and are not registered under the U.S. Securities Act. The company also said that, effective August 15, 2025, Kevin Malone is no longer serving as an advisor to the board following termination of his agreement. Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD and spun out its OTC version to a company, Celly Nutrition Corp., led by industry veterans. Quantum BioPharma retains ownership of 25.71% of Celly Nutrition at https://www.unbuzzd.com.
The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.